These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37337448)

  • 1. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
    Mbavha BT; Thelingwani RS; Chikwambi Z; Nyakabau AM; Masimirembwa C;
    Br J Clin Pharmacol; 2023 Oct; 89(10):3209-3216. PubMed ID: 37337448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.
    Thorén L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
    Br J Clin Pharmacol; 2021 Mar; 87(3):1243-1252. PubMed ID: 32713032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
    Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
    Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
    Fernández-Santander A; Gaibar M; Novillo A; Romero-Lorca A; Rubio M; Chicharro LM; Tejerina A; Bandrés F
    PLoS One; 2013; 8(7):e70183. PubMed ID: 23922954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
    Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
    Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
    Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
    BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen.
    Sanchez-Spitman AB; Swen JJ; Dezentje VO; Moes DJAR; Gelderblom H; Guchelaar HJ
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):523-536. PubMed ID: 31008668
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
    Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
    Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and CYP2D6: a contradiction of data.
    Hertz DL; McLeod HL; Irvin WJ
    Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solanidine Metabolites as Diet-Derived Biomarkers of CYP2D6-Mediated Tamoxifen Metabolism in Breast Cancer Patients.
    Medwid S; Schwarz UI; Choi YH; Keller D; Ross C; Kim RB
    Clin Pharmacol Ther; 2024 Nov; 116(5):1269-1277. PubMed ID: 39039708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.